What is BioCryst Pharmaceuticals's free cash flow yield?

BioCryst Pharmaceuticals (BCRX) reported free cash flow yield of 13% in Q1 2026.

What is the long-term trend for BioCryst Pharmaceuticals's free cash flow yield?

Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's free cash flow yield has grown at a 20.0% compound annual growth rate (CAGR), from -10.1% to 21%.

What does free cash flow yield mean?

Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.

BioCryst Pharmaceuticals BCRX Free cash flow yield

Free cash flow yield at other companies

Ionis PharmaceuticalsIONS

-11.6%+15.9pp

Ultragenyx PharmaceuticalRARE

-24.4%-252pp

ANI PharmaceuticalsANIP

11.1%+6.5pp

AnaptysBio, Inc.ANAB

0.3%+0.1pp

BridgeBio PharmaBBIO

-3.1%—

Arrowhead ResearchARWR

0.5%+0.3pp

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

free cash flow/market cap=13%

Based on trailing twelve months.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's free cash flow yield?: BioCryst Pharmaceuticals (BCRX) reported free cash flow yield of 13% in Q1 2026.
What is the long-term trend for BioCryst Pharmaceuticals's free cash flow yield?: Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's free cash flow yield has grown at a 20.0% compound annual growth rate (CAGR), from -10.1% to 21%.
What does free cash flow yield mean?: Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.